CONTAIN: Assessing the Effect of Contact Isolation on Nosocomial Colonization With ESBL-EC in German Hematology/Oncology Wards

Sponsor
University of Cologne (Other)
Overall Status
Unknown status
CT.gov ID
NCT02456818
Collaborator
University Hospital Tuebingen (Other), Universitätsklinikum Hamburg-Eppendorf (Other), University Hospital, Aachen (Other)
2,264
17

Study Details

Study Description

Brief Summary

This study aims to evaluate the impact of contact isolation on the rate of hospital-acquired transmissions of ESBL-producing Escherichia coli (ESBL-EC) and the rate of colonization and infection. On the basis of this study, it will be possible to re-evaluate the need for contact isolation for patients colonized or infected with ESBL-EC.

Detailed Description

The study aims to evaluate the impact of contact isolation on the rate of hospital-acquired transmissions of ESBL-producing Escherichia coli and the rate of colonization and infection.

Hematological and oncological wards in hospitals with a non-outbreak setting for ESBL-EC and adhering to at least the following standard of care are eligible for study participation:

  • Fecal screening for the presence of ESBL-EC of all patients within 72 hours of each admission by use of a rectal swab or stool sample

  • Follow-up fecal screening once a week and within 72 hours of discharge

  • Implementation of clinical standards aimed at ESBL-EC decolonization is not allowed on wards participating in this study, including in the context of clinical studies.

Sites will be grouped according to their approach regarding contact isolation (see group description).

As a control for external factors a hand hygiene program, including training and adherence assessments, will be implemented.

Study Design

Study Type:
Observational
Anticipated Enrollment :
2264 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Hospital-based Cohort Study in German Hematological / Oncological Wards to Assess the Effect of Contact Isolation on Nosocomial Colonization With ESBL-producing Escherichia Coli (CONTAIN Study)
Study Start Date :
Jan 1, 2015
Anticipated Primary Completion Date :
Jun 1, 2016
Anticipated Study Completion Date :
Jun 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Centers using contact isolation

Isolation triggered by the detection of ESBL-EC at hospital admission in surveillance screening or during the hospitalization by weekly screening or clinical cultures Contact isolation terminated, after at least two negative consecutive fecal screening cultures Contact isolation resumed, if subsequent ESBL-EC positive cultures are identified for the same patient including readmissions Contact isolation must include: Patient placement in single rooms Cohorting only possible, when no single rooms available and corresponding ESBL-EC strains are phenotypically identical Staff and visitors wearing gloves and gowns as contact precautions when entering the room, patient when leaving the room

Centers using no contact isolation

not regularly isolating for ESBL-EC ESBL-EC colonized or infected patients with urinary or fecal incontinence or diarrhea (>3 loose bowel movements/day) isolated in single rooms with above described contact precautions

Outcome Measures

Primary Outcome Measures

  1. Incidence of hospital-acquired ESBL-EC colonization or infection [up to 12 month]

Secondary Outcome Measures

  1. Incidence of patient-to-patient transmission of ESBL-EC defined by the isolation of two or more ESBL-EC strains from two or more different patients with overlapping hospitalization periods in the same ward, related to each other on the basis of molecular [up to 12 month]

  2. Incidence of ESBL-EC intestinal colonization among all patients (colonization is defined as the isolation of ESBL-EC in material from fecal screening) [up to 12 month]

  3. Incidence of ESBL-EC bloodstream infections among all patients (ESBL-EC bloodstream infection is defined by the isolation of ESBL-EC from blood cultures) [up to 12 month]

  4. Incidence of ESBL-EC bloodstream infections among previously colonized patients - Readmission fraction associated with infection with ESBL-EC [up to 12 month]

  5. Incidence of ESBL-Klebsiella pneumonia (ESBL-KP) colonized patients among all patients (colonization is defined as the isolation of ESBL-KP in material from fecal screening) [up to 12 month]

    In theory, the ability to produce ESBL can be transferred between species by plasmids. However, in clinical practice, this seems to be an extremely rare event. Nevertheless, it should be assessed to detect any potential risks to patients at sites not isolating for ESBL-EC.

  6. Incidence of ESBL-KP bloodstream infections among all patients (ESBL-EC bloodstream infection is defined by the isolation of ESBL-KP from blood cultures) [up to 12 month]

    In theory, the ability to produce ESBL can be transferred between species by plasmids. However, in clinical practice, this seems to be an extremely rare event. Nevertheless, it should be assessed to detect any potential risks to patients at sites not isolating for ESBL-EC.

  7. Incidence of ESBL-KP bloodstream infections among previously colonized patients [up to 12 month]

    In theory, the ability to produce ESBL can be transferred between species by plasmids. However, in clinical practice, this seems to be an extremely rare event. Nevertheless, it should be assessed to detect any potential risks to patients at sites not isolating for ESBL-EC.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Wards adhering to at least the following standard of care are eligible for study participation:

  • Fecal screening for the presence of ESBL-EC of all patients within 72 hours of each admission by use of a rectal swab or stool sample

  • Follow-up fecal screening once a week and within 72 hours of discharge

Exclusion Criteria:
  • none

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Cologne
  • University Hospital Tuebingen
  • Universitätsklinikum Hamburg-Eppendorf
  • University Hospital, Aachen

Investigators

  • Principal Investigator: Maria JG Vehreschild, PD Dr., university clinic of cologne
  • Principal Investigator: Oliver A Cornely, Prof Dr., university clinic of cologne
  • Principal Investigator: Jörg J Vehreschild, PD Dr., university clinic of cologne
  • Principal Investigator: Harald Seifert, Prof. Dr., university clinic of cologne

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Maria J.G.T. Vehreschild, PD Dr.med, University of Cologne
ClinicalTrials.gov Identifier:
NCT02456818
Other Study ID Numbers:
  • CONTAIN
First Posted:
May 29, 2015
Last Update Posted:
Feb 8, 2016
Last Verified:
Feb 1, 2016

Study Results

No Results Posted as of Feb 8, 2016